1207818280

The introduction of approved antibody tests to complement diagnostic testing using PCR allows for much greater understanding of the virus

Types of Testing

Diagnostic Testing (PCR*)

Shows if you have an active » coronavirus infection

r

Antibody Testing

Detects antibodies the immune system develops in response to a previous coronavirus infection

Estimated rates of viral detection for SARS-CoV-2

Relative probability of detection

Antibody detection likely positive PCR likely negative

PCR likely positive Infection after symptom onset

Recovery

surę

i

55 manufacturers approved"

I / Nasal or throat swab (mucus). // spit in Container (saliva)

Inform medical treatment

Indicate quarantine or hospitalisation depending on severity of symptoms

Q 0 Trigger contact tracing protocols

Finger stick or blood draw (blood)

śo ’    11 manufacturers approved‘*

Provide data for public '*■ policies

?Provide indication of

potential futurę immunity (nb. it is still unknown whether the presence of antibodies provide immunity and, ifso, for how long)

SARS- Infection CoV-2 before expo- symptom

onset

IgG antibody

Bronchoalveolar Lavage/sputum PCR

IgM antibody Nasopharingeal swab PCR

Time sińce exposure (weeks)

Provide data for public '" policies

Notę:    * Reverse transcription polymerase Chain reaction; ”Approved by the FDA as oł 18 May 2020

O 2020 L E K. Consulting LLC

Source: FDA: Interpreting Diagnostic Tests for SARS-CoV-2. Sethuraman et al, 6 May 2020 5